Health technology
is global business

Revenio Group Corporation
Annual Report 2018

CEO’s Review

“We have updated our strategy with the goal of further strengthening our global position through strong growth.“

The year 2018 was a year of strong and profitable growth for us. Sales increased in all key market areas, which we are very pleased with.

During the year, we invested heavily in product marketing that supports our growth and the launch of new products. It should be noted that all our current products are less than five years old, which indicates that our product portfolio is up-to-date. During 2018, we also strengthened our organization to support sales growth, especially in the Far East and the United States.

- Timo Hildén, President and CEO Revenio Group Corporation

Read CEO’s Review

Key figures 2018

30.7 M€

Net sales

14.4%

Net sales increased

10.2 M€

Operating profit

25.7%

Operating profit increased

0.339 €

Earnings per share, undiluted

0.28 €*

Dividend
*Board’s proposal to the
Annual General Meeting
See all key figures
“Our growth objectives are supported by global megatrends in health care, such as population growth and ageing.“

Our high quality and reliable products

Corporate responsibility

"Corporate responsibility and sustainable development are an essential part of our strategy and an integral part of the common values that are important to us."

Responsibility lies at the heart of our operations, starting all the way from product development to the products and technologies as well as their operation visible to our end customers. It is important for us that our products are of high quality, reliable, and safe and easy to use. Our product development takes our customers' wishes and feedback into account.

Navigate to Revenio's mainpage

InvestorsMediaContact